Concert Pharmaceuticals, Inc. (CNCE) News
Filter CNCE News Items
CNCE News Results
|Loading, please wait...|
CNCE News Highlights
- For CNCE, its 30 day story count is now at 2.
- Over the past 7 days, the trend for CNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BEAT are the most mentioned tickers in articles about CNCE.
Latest CNCE News From Around the Web
Below are the latest news stories about Concert Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNCE as an investment opportunity.
LEXINGTON, Mass., February 24, 2022--Concert to report 2021 financial results before the markets open on March 3, 2022.
Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
LEXINGTON, Mass., January 04, 2022--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.
LEXINGTON, Mass., January 03, 2022--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.
Every investor in Concert Pharmaceuticals, Inc. ( NASDAQ:CNCE ) should be aware of the most powerful shareholder...
Investors need to pay close attention to Concert Pharmaceuticals (CNCE) stock based on the movements in the options market lately.
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) CEO Roger D. Tung sold 6,700 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $3.62, for a total transaction of $24,254.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this 
Marshall Wace LLP reduced its position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 61.2% in the 2nd quarter, Holdings Channel reports. The firm owned 20,455 shares of the biotechnology companys stock after selling 32,226 shares during the period. Marshall Wace LLPs holdings in Concert Pharmaceuticals were worth $86,000 as of its most recent filing with the 
Vanguard Group Inc. lessened its stake in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 10.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,238,016 shares of the biotechnology companys stock after selling 152,050 shares during the period. Vanguard Group Inc. owned 3.85% of Concert 
Truist Securiti Research Analysts Increase Earnings Estimates for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Stock analysts at Truist Securiti increased their FY2021 earnings per share estimates for Concert Pharmaceuticals in a research note issued on Tuesday, November 9th. Truist Securiti analyst J. Lee now expects that the biotechnology company will post earnings of ($1.89) per share for the year, up from their prior estimate